Optimize IAS
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2027
    • Mains Mentorship
      • Arjuna 2027 Mains Mentorship
      • Arjuna 2026 Mains Mentorship
      • Mains Master Notes
  • Portal
    • Sign Up
    • Sign In
  • Our App
    • Android App
    • iOS App
  • Contact Us
    • Home
    • About Us
    • Courses
      • Prelims Test Series
        • LAQSHYA 2027
      • Mains Mentorship
        • Arjuna 2027 Mains Mentorship
        • Arjuna 2026 Mains Mentorship
        • Mains Master Notes
    • Portal
      • Sign Up
      • Sign In
    • Our App
      • Android App
      • iOS App
    • Contact Us

    Psoriasis

    • July 19, 2020
    • Posted by: OptimizeIAS Team
    • Category: DPN Topics
    No Comments

    Subject: Science and tech

    Context:

    Itolizumab, a monoclonal antibody used to treat acute psoriasis has got regulatory approval to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome patients due to COVID-19.

    Concept:

    • Psoriasis is a skin disease that causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp.
    • Psoriasis is a common, long-term (chronic) disease with no cure.
    • Psoriasis is thought to be an immune system problem that causes the skin to regenerate at faster than normal rates. In the most common type of psoriasis, known as plaque psoriasis, this rapid turnover of cells results in scales and red patches.
    Psoriasis Science and tech
    Footer logo
    Copyright © 2015 MasterStudy Theme by Stylemix Themes
        Search